ENDOTHELIAL DYSFUNCTION SCORES IN CHILDREN WITH TYPE 1 DIABETES WHO HAVE SUFFERED COVID-19 INFECTION

Sadirkhodjaeva Azizakhon Alavitdinovna; Ashurova Dilfuza Tashpulatovna

doi:10.5281/zenodo.10884863

ENDOTHELIAL DYSFUNCTION SCORES IN CHILDREN WITH TYPE 1 DIABETES WHO HAVE SUFFERED COVID-19 INFECTION

27.03.2024 International Scientific Journal "Science and Innovation". Series D. Volume 3 Issue 3

Sadirkhodjaeva Azizakhon Alavitdinovna, Ashurova Dilfuza Tashpulatovna

Abstract. To analyze the relationship of endothelial dysfunction in children with type 1 diabetes mellitus who have suffered a COVID-19 infection. Research materials and methods. For our study, 140 children with type 1 diabetes who suffered from COVID-19 were treated in the children's department of the RSNPMC endocrinology aged 2 to 18 years. The comparison group was 65 children with type 1 diabetes, a group of 15 practical healthy children matched for age and sex without any signs or symptoms of cardiovascular disease was used as a control. The work uses biochemical, immunological research methods and statistical research methods. According to our studies, it was revealed that SD1 is an important risk factor affecting the clinical severity of COVID-19 disease. Immune and inflammatory response in children with 1 DM who have undergone COVID-19 infection leads to endothelial dysfunction with an increase in the concentration of HF CRP, and VEGF. A special response was also identified with an increase in AT to the myocardial antigen, which proved the role of myocardial damage.

Keywords: type 1 diabetes mellitus, children, endothelial dysfunction, COVID-19

References:

1. Беленков Ю.Н., Агеев Ф.Т., Мареева В.Ю. Нейро-гормоны и цитокины при сердечной недостаточности: новая теория старого заболевания? // Сердечная недостаточность. 2000, №4 (1), С.135-138. 2. Берне С.А., Клименкова А.В., Шмидт Е.А., Авра-менко О.Е., Селезнева Е.С., Барбараш О.Л. Провоспали-тельные цитокины при остром коронарном синдроме в сочетании с сахарным диабетом 2 типа // Кардиоваскулярная терапия и профилактика. 2008, №7(6), Приложение 1, С.49. 3. Васина Л.В., Петрищев Н.Н., Власов Т.Д. Эндотелиальная дисфункция и ее основные маркеры // Регионарное кровообращение и микроциркуляция. - 2017. - Т.16. - №1. - С. 4-15. 4. Говорин А.В. Некоронарогенные поражения миокарда // Новосибирск: Наука, 2014. - 448 с. 5. Васина Л.В., Власов Т.Д., Петрищев Н.Н. Функциональная гетерогенность эндотелия (обзор) // Артериальная гипертензия. - 2017. - Т.23. - №2. - С. 88-102. 6. Мельникова Ю.С., Макарова Т.П. Эндотелиальная дисфункция как центральное звено патогенеза хронических болезней // Казанский медицинский журнал. - 2015. - Т.96. - №4. - C. 659-665. 7. Власов Т.Д., Нестерович И.И., Шиманьски Д.А. Эндотелиальная дисфункция: от частного к общему. Возврат к «старой парадигме»? // Регионарное кровообращение и микроциркуляция. - 2019. - Т.18. - №2. - С. 19-27. 8. Омельченко В.П., Затонский С.А., Демидова А.А., Демидов И.А. Прогнозирование прогрессирования хронической сердечной недостаточности ишемического генеза с учетом иммунологических показателей // Фундаментальные исследования. 2014, №4, С. 325-329. 9. Chiarelli F., Spagnoli A., Basciani F., Tumini S., Mezzetti A., Cipollone F., Cuccurullo F., Morgese G., Verrotti A. Vascular endothelial growth factor (VEGF) in children, adolescents and young adults with Type 1 diabetes mellitus: Relation to glycaemic control and microvascular complications. Diabet. Med. 2000;17:650–656. doi: 10.1046/j.1464-5491.2000.00350.x. 10. Gregory J.M., Slaughter J.C., Duffus S.H., Smith T.J., Le Stourgeon L.M., Jaser S.S., Mc Coy A.B., Luther J.M., Giovannetti E.R., Boeder S., et al. COVID-19 Severity Is Tripled in the Diabetes Community: A Prospective Analysis of the Pandemic’s Im-pact in Type 1 and Type 2 Diabetes. Diabetes Care. 2021;44:526–532. doi: 10.2337/dc20-2260. 11. Ilic I., Ilic M. Diabetes Mellitus after SARS-CoV-2 Infection: An Epidemiological Review. Life. 2023;13:1233. doi: 10.3390/life13061233 12. Mohseni Afshar Z., Babazadeh A., Janbakhsh A., Mansouri F., Sio T.T., Sullman M.J.M., Carson-Chahhoud K., Hosseinzadeh R., Barary M., Ebrahimpour S. Coronavirus disease 2019 (COVID-19) vaccination recommendations in special populations and pa-tients with existing comorbidities. Rev. Med. Virol. 2022;32:e2309. 13. Muñoz C.E., Chao L.C. Impact of COVID-19 on Youth with Type 2 Diabetes: Lessons Learned from a Pediatric Endocrinologist and a Psychologist. Front. Endocrinol. 2021;12:650492. doi: 10.3389/fendo.2021.650492. 14. Ng S.M. COVID-19 and children with diabetes: Emerging knowledge. Pract. Diabetes. 2020;37:147–148a. doi: 10.1002/pdi.2289. 15. Pal R., Bhadada S.K., Misra A. COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges. Diabetes Metab. Syndr. 2021;15:505–508. doi: 10.1016/j.dsx.2021.02.026. 16. Sena CM, Pereira AM, Seiça R. Endothelial dysfunction - a major mediator of diabetic vascular disease. Biochimica Biophysica Acta. 2013;1832:2216-2231. 17. Torimoto K, Okada Y, Tanaka Y. Type 2 diabetes and vascular endothelial dysfunction. J Uoeh. 2018;40(1):65-75. 18. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020;323:1239–1242. doi: 10.1001/jama.2020.2648.